NKTX:NASDAQ, Nkarta, Inc.

NKTX stock overview

Nkarta, Inc. (NKTX:NASDAQ) closed at $1.14 on November 20, 2026, up 1.34% on the day. The stock trades 69.5% below its 52-week high of $3.72 and 2.7% above its 52-week low of $1.11. Over the past year, it lost 36.9%. Nkarta, Inc. is part of the Health Care sector.

Key figures

Price
$1.14
Day change
+1.34%
Volume
1,603,335
Average volume
1,008,325
Market cap
81M+
52-week range
$1.11 – $3.72
50-day average
$2.06
200-day average
$2.47

Price action over the past year

In 252 trading sessions since November 20, 2025, NKTX closed higher on 122 days (48%). Its best day was April 17, 2026 (+23.93%) and its worst was November 10, 2026 (-15.09%). The stock moved 10% or more in a single session 10 times.

Recent signals

NKTX news

About Nkarta, Inc.

Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment.

Similar stocks

Find more stocks like NKTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.